Abstracts tagged "fibromyalgia"

Abstract Number: 1323 • ACR Convergence 2024
Drug Abuse Screening in Patients Who Fulfill the 2016 Fibromyalgia Criteria
Laura Aline Martinez-Martinez¹, Angelica Beltran-Barajas², Mayra Nadia Quintanar-Cuevas³, David Vera Bustamante⁴, Itzel Palafox Sosa⁵, Karyme Zazil Velazquez-Zarza⁶, Salvador Zuñiga-Roman⁶ and Luz Angelica Viruel-Mejia⁷, ¹Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, ²Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, Mexico City, ³Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ⁴Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, ⁷Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico
Background/Purpose: The clinical association of fibromyalgia with symptoms of anxiety and depression is well recognized [Uçar M, et al. J Int Med Res 2015;43(5):679-85]. Emotional…
Abstract Number: 1156 • ACR Convergence 2024
Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Juan Schmukler², Kristin Wipfler³, Christopher G McKennan⁴, Jiaxuan Duan⁴, Kaleb Michaud⁵ and Yvonne Lee⁶, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Division of Rheumatology, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Pittsburgh, Department of Statistics, Pittsburgh, PA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Northwestern University, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is the prototypical central pain disorder that can be associated with rheumatic conditions such as rheumatoid arthritis, Sjogren’s disease and lupus. Patients…
Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Jennifer Rogers¹, Megan Clowse², David Pisetsky³, Jayanth Doss⁴, Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Rebecca Sadun⁴, Kai Sun⁴ and Amanda Eudy⁶, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…
Abstract Number: 1178 • ACR Convergence 2024
Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?
Nancy Baker¹, Aliza Spielman¹ and Robert Edwards², ¹Tufts University, Medford, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a common and disabling condition characterized by widespread muscular pain. Meditation has been shown to alleviate affective pain in people with…
Abstract Number: 2163 • ACR Convergence 2024
Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Marc Blanchard¹, Cinja Koller², Patrick Hermann¹, Johanna Mettler¹, Tiffany Prétat³, Pedro Ming Azevedo³ and Thomas Hügle³, ¹Lausanne University Hospital, Lausanne, Vaud, Switzerland, ²Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal…
Abstract Number: 1212 • ACR Convergence 2024
Childhood Maltreatment Increases Risk of Chronic Widespread Pain: Counterfactual Analysis of UK Biobank
Kate Timmins¹, Tim Hales² and Gary Macfarlane¹, and The Consortium Against Pain inEquality Investigators and Advisory Group, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Dundee, Dundee, United Kingdom
Background/Purpose: Adverse childhood experiences (ACEs), including maltreatment (abuse and neglect), have been associated with chronic pain, but the evidence is largely cross-sectional. Existing evidence is…
Abstract Number: 2173 • ACR Convergence 2024
Hope and Health in Adolescents with Chronic Musculoskeletal Pain
Irene Chern¹, Mackenzie McGill², Nellie P Butler² and Sabrina Gmuca², ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Hope, the capability to derive pathways to desired goals and motivate oneself via agency thinking plays a protective role in pediatric health contributing to…
Abstract Number: 1218 • ACR Convergence 2024
Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
Seth Lederman¹, Lesley Arnold², Mary Kelley¹, Ben Vaughn³, Jean Engels¹ and Gregory Sullivan¹, ¹Tonix Pharmaceuticals, Inc, Chatham, NJ, ²University of Cincinnati College of Medicine, Cincinnati, OH, ³Rho, Inc, Chapel Hill, NC
Background/Purpose: Fibromyalgia (FM) is a nociplastic syndrome of chronic widespread pain, nonrestorative sleep, fatigue, cognitive dysfunction and mood symptoms. RESILIENT was a confirmatory Phase 3…
Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Gilad Halpert¹, Eri Govrin², Boris Gilburd³, Shlomo Segev³, Omer Gendelman⁴, Abdulla Watad⁵, Yehuda Shoenfeld⁶, David Meiri⁷ and Howard Amital⁸, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Sdot Micha, Israel, ³Sheba Medical Center, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶sheba medical center , Israel, Ramat Gan, Israel, ⁷Technion-Israel Institute of Technology, Haifa, Israel, ⁸Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
Abstract Number: 1219 • ACR Convergence 2024
Association Between Fibromyalgia and Serum Levels of Calcitonin Gene-Related Peptide and Vascular Endothelial Growth Factor: A Meta-Analysis
Osama Al Zoubi¹, Dahlia Chavez² and Robert Katz³, ¹University of Illinois at Chicago, Chicago, IL, ²Rheumatology Associates, Rush University Medical Center, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia syndrome (FMS) is characterized by generalized muscle pain, fatigue, psychological distress, cognitive dysfunction, and sleep disturbances. The physiopathology of FMS is not fully…
Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Gilad Halpert¹, Ori Moskovitch², Linoy Israel², Eri Govrin², Boris Gilburd², Ori Segal², Adi Anaki³, Tal Caller², Daniel Yechiali², Shlomo Segev², Omer Gendelman⁴, Abdulla Watad⁵, Ruty Mehrian-Shai², Rachella Popovtzer³ and Howard Amital⁶, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Ramat-Gan, Israel, ³Bar Ilan University, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
Abstract Number: 1220 • ACR Convergence 2024
Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Seth Adler¹, Osama Al Zoubi² and Robert Katz³, ¹Rheumatology Associates, Rush University Medical Center, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Recent estimates predict that up to 12 million adults in the United States suffer from Fibromyalgia Syndrome (FMS). That is compared to around 1.3…
Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Marc Blanchard¹, Pedro Ming Azevedo², Tiffany Prétat², Cinja Koller² and Thomas Hügle³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²Lausanne University Hospital, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…
Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Timothy Demchak¹, Ernesto Leal-Junior², Neide Ribeiro², Heliodora Casalechi², Douglas Johnson³ and Shaiane Tomazoni⁴, ¹Indiana State University, Terre Haute, IN, ²Nove de Julho University, São Paulo, Brazil, ³Multi Radiance Medical, Solon, OH, ⁴University of Bergen, Bergen, Norway
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].